Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.
- Record quarterly revenue of approximately $1.42 million
- Empax network reaches 90 dosing sessions per week across four states
- More than 40 DVA referrals, with first treatment approvals received
- Former US Veterans Affairs Secretary Dr David Shulkin appointed strategic adviser
- Quarter-end cash of $4.745 million against $2.282 million quarterly operating outflows
Revenue reaches a quarterly record as Sydney joins the network
Emyria Limited (ASX:EMD) has moved from expanding its clinic footprint to testing whether that footprint can produce repeatable revenue, reporting approximately $1.42 million for the September quarter. That was up from about $0.47 million in the corresponding quarter a year earlier, while a further approximately $725,000 of earned revenue had yet to be received in cash.
The company opened its first Sydney Empax clinic during September, taking the network into New South Wales and four Australian states. The addition lifted treatment capacity from 14 to 18 beds, or up to 90 dosing sessions a week, although the filing says work is still under way to build referrer awareness and patient flows at the new site.
Operational capacity is also being rebuilt elsewhere. Perth added two authorised prescribers and Brisbane began onboarding three, while Victoria is preparing to bring on a second authorised prescriber in the fourth quarter of calendar 2026. Emyria also trained 15 therapists in Perth, with further recruitment and practical training expected before additional capacity becomes visible in the first quarter of 2027. This builds on the Q4 dosing capacity expansion, which had previously identified prescriber constraints and therapist availability as hurdles to treatment growth.
DVA approvals create an early test of veteran demand
The first approvals for eligible Department of Veterans’ Affairs patients arrived after the quarter, giving Emyria a new funding channel to convert into treatment activity. More than 40 DVA referrals are currently in the network, although patients still need to pass screening and application processes before treatment begins.
That makes the DVA pipeline an important near-term measure of whether the expanded network can be filled, rather than simply made larger. The company says its immediate focus is to start the first DVA-funded treatments and increase utilisation at Sydney, but the release does not quantify expected revenue from the referrals.
US profile rises while commercial outcomes remain uncontracted
Emyria’s international profile advanced during the period after Executive Chair Greg Hutchinson presented the company’s Australian treatment experience at the US Food and Drug Administration’s 14 September public hearing on psychedelic medicines. The appearance followed the FDA psychedelic hearing appearance, which centred on Emyria’s delivery model rather than an approval, funding award or disclosed commercial agreement.
The company has since appointed former US Veterans Affairs Secretary Dr David Shulkin as a strategic adviser. Emyria says he will support its pursuit and assessment of partnerships and commercial opportunities across US healthcare, veterans’ health, research and treatment delivery. Separately, it is in late-stage discussions with an international pharmaceutical sponsor that could become the second participant in its Empax Global Partnership Program, though no agreement has been finalised.
Cash burn leaves expansion dependent on operating progress
Cash receipts totalled approximately $1.60 million during the quarter, but net operating cash outflows were $2.282 million. Emyria ended September with $4.745 million in cash and no disclosed financing facilities, producing the Appendix 4C estimate of 2.08 quarters of funding at the reported burn rate. The calculation is based on a single quarter and may change as revenue, clinic utilisation and spending move.
The cash position also keeps alive the concern raised in the FY26 funding warning, when the annual report recorded higher operating cash outflows and an auditor-highlighted uncertainty over funding continuity. The next quarter should show whether Sydney and DVA activity improve cash conversion quickly enough to offset the investment required to operate a national network.
Bottom Line?
The expansion story is gaining operational substance, but Sydney utilisation, DVA-funded treatments and cash conversion now need to catch up with the company’s growth ambitions.
Questions in the middle?
- How quickly will the 40-plus DVA referrals convert into funded treatments and revenue?
- Can Sydney build utilisation before the network’s expanded staffing and medication costs weigh further on cash?
- Will Dr Shulkin’s appointment or the pharmaceutical discussions produce a contracted US or partnership opportunity?